This study is about testing a drug called RAP-219 for adults with a type of epilepsy that doesn't get better with usual treatments, called Refractory Focal Epilepsy. The study aims to see if RAP-219 is safe and works well. It's a Phase 2A study, meaning it is in an early stage of testing. The study will involve about 20 people who already have a special device called the RNS® system implanted to help control their seizures. The device is placed where seizures start in the brain.
To join, participants should have had at least one seizure in the past 8 weeks and be willing to follow study rules. They should not have had certain types of seizures in the last 10 years. Also, women who can have children must use two types of birth control.
- Length: The study is multi-center and open-label, meaning you and the researchers will know what treatment is being given.
- Participation: Involves around 20 participants with a device already implanted for seizures.
- Risks: Participants must not have had surgery or severe seizures recently.
How understandable was the trial content above?
Hard to understand
Easy to understand